In vitro bactericidal activity of trimethoprim-sulfamethoxazole alone and in combination with colistin against carbapenem-resistant Acinetobacter baumannii clinical isolates

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 11, 2016, Pages 6903-6906

  Nepka, Martha ^a   Perivolioti, Efstathia ^a   Kraniotaki, Eleni ^a   Politi, Lida ^b   Tsakris, Athanasios ^b   Pournaras, Spyros ^b  

^a EVANGELISMOS HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN; COTRIMOXAZOLE; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; COLONY FORMING UNIT; CONTROLLED STUDY; DISEASE SEVERITY; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; ACINETOBACTER INFECTIONS; DRUG EFFECTS; DRUG POTENTIATION; GENETICS; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; CARBAPENEMS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; HUMANS; MICROBIAL SENSITIVITY TESTS; TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION;

EID: 84994493498     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01082-16     Document Type: Article

References (18)

1. Fournier PE, Richet H. 2006. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 42:692-699. http://dx.doi.org/10.1086/500202.
2. European Centre for Disease Prevention and Control. 2015. Annual epidemiological report 2014: antimicrobial resistance and healthcare-associated infections. ECDC, Stockholm, Sweden.
3. Wormser GP, Keusch GT, Heel RC. 1982. Co-trimoxazole (trimethoprim-sulfamethoxazole): an updated review of its antibacterial activity and clinical efficacy. Drugs 24:459-518. http://dx.doi.org/10.2165/00003495-198224060-00002.
4. Clinical and Laboratory Standards Institute. 2015. Performance standards for antimicrobial susceptibility testing; 25th informational supplement. June 2015 update. Document M100-S25U. CLSI, Wayne, PA.
5. European Committee on Antimicrobial Susceptibility Testing. 2015. Breakpoint tables for interpretation of MICs and zone diameters, version 5.0. EUCAST, Basel, Switzerland.
6. Livermore DM, Mushtaq S, Warner M, Woodford N. 2014. Comparative in vitro activity of sulfametrole/trimethoprim and sulfamethoxazole/trimethoprim and other agents against multiresistant Gram-negative bacteria. J Antimicrob Chemother 69:1050-1056. http://dx.doi.org/10.1093/jac/dkt455.
7. OXA-51-like genes for rapid assignment of Acinetobacter baumannii clinical isolates to international clonal lineages. J Clin Microbiol 52:1653-1657. http://dx.doi.org/10.1128/JCM.03565-13.
8. Gogou V, Pournaras S, Giannouli M, Voulgari E, Piperaki ET, Zarrilli R, Tsakris A. 2011. Evolution of multidrug-resistant Acinetobacter baumannii clonal lineages: a 10 year study in Greece (2000-09). J Antimicrob Chemother 66:2767-2772. http://dx.doi.org/10.1093/jac/dkr390.
9. Gleckman R, Gantz NM, Joubert DW. 1981. Intravenous sulfamethoxazole-trimethoprim: pharmacokinetics, therapeutic indications, and adverse reactions. Pharmacotherapy 1:206-211. http://dx.doi.org/10.1002/j.1875-9114.1981.tb02542.x.
10. Svedhem A, Iwarso S. 1979. Cerebrospinal fluid concentrations of trimethoprim during oral and parenteral treatment. J Antimicrob Chemother 5:717-720. http://dx.doi.org/10.1093/jac/5.6.717.
11. Gurjar M. 2015. Colistin for lung infection: an update. J Intensive Care 3(1):3. http://dx.doi.org/10.1186/s40560-015-0072-9.
12. Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, Karaiskos I, Poulakou G, Kontopidou F, Armaganidis A, Cars O, Giamarellou H. 2009. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 53:3430-3436. http://dx.doi.org/10.1128/AAC.01361-08.
13. Pachón-Ibáñez ME, Docobo-Pérez F, López-Rojas R, Domínguez-Herrera J, Jiménez-Mejias ME, García-Curiel A, Pichardo C, Jiménez L, Pachón J. 2010. Efficacy of rifampin and its combinations with imipenem, sulbactam and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 54:1165-1172. http://dx.doi.org/10.1128/AAC.00367-09.
14. Principe L, D'Arezzo S, Capone A, Petrosillo N, Visca P. 2009. In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii. Ann Clin Microbiol Antimicrob 8:18. http://dx.doi.org/10.1186/1476-0711-8-18.
15. Falagas ME, Vardakas KZ, Roussos NS. 2015. Trimethoprim/sulfamethoxazole for Acinetobacter spp.: a review of current microbiological and clinical evidence. Int J Antimicrob Agents 46:231-241. http://dx.doi.org/10.1016/j.ijantimicag.2015.04.002.
16. Tripodi MF, Durante-Mangoni E, Fortunato R, Utili R, Zarrilli R. 2007. Comparative activities of colistin, rifampicin, imipenem and sulbactam/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases. Int J Antimicrob Agents 30:537-540. http://dx.doi.org/10.1016/j.ijantimicag.2007.07.007.
17. Ni W, Shao X, Di X, Cui J, Wang R, Liu Y. 2015. In vitro synergy of polymyxins with other antibiotics for Acinetobacter baumannii: a systematic review and meta-analysis. Int J Antimicrob Agents 45:8-18. http://dx.doi.org/10.1016/j.ijantimicag.2014.10.002.
18. Vidaillac C, Benichou L, Duval RE. 2012. In vitro synergy of colistin combinations against colistin-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae isolates. Antimicrob Agents Chemother 56:4856-4861. http://dx.doi.org/10.1128/AAC.05996-11.